U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1449



OF ART STED BY APPLICANT

ATTY. DOCKET: 17656 CON (OCU)	SERIAL NO.: 10/671,816
APPLICANT: VERNON G. WONG et al.	TITLE: METHODS FOR TREATING INFLAMMATION- MEDIATED CONDITIONS OF THE EYE
FILING DATE: September 23, 2003	GROUP: 1615

#### **U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (If applicable)
CR	AA	4,997,652	3/5/1991	Wong, Vernon G.			
1	AB	5,164,188	11/17/1992	Wong, Vernon G.			•
	AC	5,443,505	8/22/1995	Wong, Vernon G.			
	AD	5,501,856	3/26/1996	Ohtori et al.			
	AE	5,766,242	6/16/1998	Wong, Vernon G.			
	AF	5,824,072	10/20/1998	Wong, Vernon G.			
$\overline{V}$	AG	5,869,079		Wong, Vernon G.			

#### **FOREIGN PATENT DOCUMENTS**

ĺ		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (ves/no)
Ì	ВА					·	

### OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

CR	CA	American Academy of Ophthalmology; Basic and Clinical Science Course: Intraocular inflammation and Uveitis Section 9, 2003-2004 57-80, 102-103, 152-156
	СВ	Apel et al.; A subconjunctival degradable implant for cyclosporine delivery in corneal transplant therapy; Current Eye Research; 1995; 659-667
	cc	Bloch-Michel, Etienne; <i>Opening Address: Intermediate Uveitis</i> ; Boke WRF, Manthey KF, Nussenblatt RB (eds): <u>Intermediate Uveitis</u> ; Dev Ophthalmol; Basel, Karger; 1992, Vol 23; 1-2
	CD	Bodor et al.; A comparison of intraocular pressure elevation activity of loteprednol etabonate and dexamethasone in rabbits; Current Eye Research, 1992, 11, 525-30
	CE	Boke WRF, Manthey KF, Nussenblatt RB (eds): Clinical Picture of Intermediate Uveitis; Intermediate Uveitis; Dev Ophthalmol; Basel, Karger; 1992, Vol 23; 20-27
V	CF	Cheng et al.; Intravitreal Sustained-Release Dexamethasone Device in the Treatment of Experimental Uveitis; Investigative Ophthalmology & Visual Science; 2/1995, Vol. 36, No. 2; 442-453

EXAMINER Close DATE CONSIDERED 12-17-04

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# LIST OF ART CITED BY APPLICANT

ATTY. DOCKET	: 17656 CON (OCU)	SERIAL NO.: 10/671,816
APPLICANT:	VERNON G. WONG et al.	TITLE: METHODS FOR TREATING INFLAMMATION- MEDIATED CONDITIONS OF THE EYE
FILING DATE:	September 23, 2003	GROUP: 1615

			·
	0.	CG	De Jong et al.; New insights into the hydrolytic degradation of poly (lactic acid):
	<u>K </u>	<u> </u>	participation of the alcohol terminum; Polymer 42 (2001) 2795-2802
	:	СН	Gould et al.; Fifty:fifty poly (DL glycolic acid-lactic acid) copolymer as a drug delivery
	{	1	system for 5-fluorouracil: a histopathological evaluation; Can J Ophthalmol, Vol. 29,
	1		No. 4, 1994; 168-171
ļ		CI :	Hayes, Robert C. Jr., Adrenocorticotropic Hormone: Adrenocortical Steroids and
	1		their Synthetic Analogs; Inhibitors of the Synthesis and Actions of Adrenocortical
		ŀ	Hormones, Chapter 60 at pg 1447 of Goodman and Gilman's: The pharmacological
	ļ.		Basis of Therapeutics, Eighth Edition, Pergamon Press1990
		C	Kwak et al.; Evaluation of the Retinal Toxicity and Pharmacokinetics of
	1 .		Dexamethasone After Intravitreal Injection; Arch Ophthalmol, Vol. 110, 2/1992, 259-
	1::		266
	.[	CK	Lee et al.; Drug delivery to the posterior segment, Chapter 25 of Principles of
			vitreoretinal therapy, Vol. 1, Part 1, 1989, 483-498
		CL	Maurice, David M.; Micropharmaceutics of the Eye; Ocular Inflammation Ther., 1;
	l ·		1983, 97-102
		СМ	Ogden et al. editors; Retina - Basic Science and Inherited Retinal Disease Vol. 1,
			St. Louis; CV Mosby
	-	CN	Olsen et al.; Human Scleral Permeability - Effects of Age, Cryotherapy,
			Transscleral Diode Laser, and Surgical Thinning, Investigative Ophthalmology &
		<u> </u>	Visual Science; 8/1995, Vol. 36, No. 9, 1893-1903
		co	Park et al.; A new preparation method for protein loaded poly (D,L-lactic-coglycolic
	1	1 .	acid) Microspheres and protein release mechanism study, Journal of Controlled
	<u> </u>	<u> </u>	Release; 55 (1998), 181-191
		CP	Renfro et al.; Ocular Effects of Topical and Systemic Steroids; Dermatologic Clinics,
			Vol. 10, No. 3, 7/1992, 505-512
		CQ	Tracy et al.; Factors affecting the degradation rate of poly (lactide-co-glycolide)
1	<u> </u>		Microspheres in vivo and in vitro; Biomaterials; 20 (1999), 1057-1062
V	d .	CR	Schwartz, Bernard; The Response of Ocular Pressure to Corticosteroids;
		·	Ophthalmol. Clin. North Am., 6; 929-89

EXAMINER DATE CONSIDERED 12-17-024

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17656 CON (OCU)	SERIAL NO.: 10/671,816
APPLICANT: VERNON G. WONG et al.	TITLE: METHODS FOR TREATING INFLAMMATION- MEDIATED CONDITIONS OF THE EYE
FILING DATE: September 23, 2003	GROUP: 1615

CR	CS	Skalka et al.; Effect of Corticosteroids on Cataract Formation; Arch Ophthalmol; Vol. 98, 10/1980, 1773-1777
	CT	Tracy et al.; Factors affecting the degradation rate of poly (lactide-co-glycolide) Microspheres in vivo and in vitro; Biomaterials; 20 (1999), 1057-1062
	CU	United States Pharmacopeia: The National Formulary 18; 1995, 1790-1798
	CV	Zhou et al.; Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy; Journal of Controlled Release; 55, 281-295
	CW	
	сх	
	. CY	
	cz	

EXAMINER DATE CONSIDERED 12-17-04

<sup>\*</sup>EXAMINER: Initial if reference considered, whether r not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCESEP 1 0 2001 & PATENT AND TRADEMARK OFFICE FORM PTO-1449

ATTY. DOCKET: 17656 CON (OCU)

SERIAL NO.: 10/671,816

APPLICANT: VERNON G. WONG et al.

TITLE: METHODS FOR TREATING INFLAMMATION-MEDIATED CONDITIONS OF THE EYE

FILING DATE: September 28, 2003

GROUP: 1615

#### **U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
CR	AA						
7	AB						
<del>/</del>	AC						
/	AD						
V	AE						

#### FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
BA				,		
8B						
 ВС						
BD						
BE						
8F						

#### **OTHER ART**

(Including Author, Title, Date, Pertinent Pages, etc.)

CR	CA	Morita Y., et al., Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly(DL-lactic acid) implants, Biol. Pharm. Bull., 1998 Feb; 21(2): 188-90.
	СВ	Nakamura O., et al., Inhibition of neovascularization and tumor growth by dexamethasone, No To Shinkei, 1992 Jan;44(1):37-41.
W.	CC	Dohlman C. et al., <i>Treatment of corneal edema with a buried implant</i> , Tr. Am. Acad. Opth. & Otol., MarApr. 1966, pp. 267-280.
	CD	
	CE	
	CF	

EXAMINER DATE CONSIDERED 12-17-04

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERO PATENT AND TRADEMARK OFFICE FORM PTO-1449

LISTERNAT CITED BY APPLICANT

ATTY. DOCKET: 17656 CON (OCU)	SERIAL NO.: 10/671,816
APPLICANT: VERNON G. WONG et al.	TITLE: METHODS FOR TREATING INFLAMMATION- MEDIATED CONDITIONS OF THE EYE
FILING DATE: September 28, 2003	GROUP: 1615

#### **U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA				-		
	AB				,		
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	Al						

#### FOREIGN PATENT DOCUMENTS

			DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
T	CR	BA	EP0430539A2	11-20-1990	EUROPE	A61K	9/22	Y
T	7	88	WO 99/11244	08-28-1998	PCT	A61K	9/32	Y
ŀ	V	ВС						
t		BD						

# OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

C	Α
Ci	B·
C	C
C	D
CI	E
CI	F

\*EXAMINER DATE CONSIDERED 27704

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.